[Urolesan in the treatment of stenocardia patients]

Area of Science:

• Cardiology
• Pharmacology
• Vascular Biology

Background:

• Chronic ischemic heart disease (CIHD) poses significant challenges in patient management.
• Microcirculatory dysfunction and coagulation abnormalities are key pathophysiological aspects of CIHD.
• Effective therapeutic strategies for CIHD, particularly for exertion stenocardia, are continuously sought.

Purpose of the Study:

• To evaluate the efficacy of Urolesan in patients suffering from chronic ischemic heart disease.
• To investigate the impact of Urolesan on microcirculation, erythrocyte aggregation, and the coagulation system.
• To assess the effects of Urolesan on peripheral circulation, external respiration, and serum aminotransferase activity.

Main Methods:

• The study involved patients diagnosed with chronic ischemic heart disease.
• Treatment with Urolesan was administered to the patient cohort.
• Key physiological and biochemical parameters were monitored before and after treatment.

Main Results:

• Urolesan demonstrated a positive effect on the vascular component of microcirculation.
• Improvements were observed in erythrocyte aggregation and peripheral circulation.
• Normalization of the blood coagulation system and serum aminotransferase activity was noted.
• Optimization of external respiration function was also a significant finding.
• These beneficial effects were most pronounced in patients with exertion stenocardia.

Conclusions:

• Urolesan shows promise as a therapeutic agent for chronic ischemic heart disease.
• The drug positively influences multiple physiological systems implicated in CIHD pathophysiology.
• Urolesan may be particularly beneficial for patients experiencing exertion stenocardia, warranting further investigation.